美国已接种带状疱疹疫苗成人加强针的成本效果
研究采用马尔可夫模型,从社会视角比较已接种者不加强与在不同时间加强的成本效果。结果显示,在初次接种后超过5年加强时每质量调整生命年成本低于10万美元,约10年时最具成本效果,结论对模型输入广泛变化稳健。
要点
- 对≥60岁已接种者,加强针在初种后超过5年时每质量调整生命年成本低于10万美元。
- 加强针在初种后约10年时最具成本效果。
- 该成本效果结论对模型输入的广泛变化稳健。
核心结论
- 在当前假设下,对初次接种≥60岁者于初种后10年给予带状疱疹疫苗加强针具有成本效果。
研究设计与样本
- 研究构建马尔可夫模型,对已接种者进行终身随访。
- 从社会视角比较不加强与加强方案的成本与质量调整生命年。
- 加强针在初种后1至20年间任一时间给予,初种年龄分别为60、70、80岁。
- 因个体进入模型时已接种,首剂成本与副作用未纳入分析。
- 假设加强针效力与消退率与初种相同,模型输入基于已发表文献,分析于2016年进行。
主要发现
- 加强针的成本效果因年龄和初种后时间而异。
- 初种后超过5年加强时,每质量调整生命年成本低于10万美元。
- 加强针在初种后约10年时最具成本效果。
- 该发现对模型输入的广泛变化稳健。
关键数值与推荐
- 成本效果阈值为每质量调整生命年10万美元。
- 加强针在初种后超过5年给予时成本低于每质量调整生命年10万美元。
- 加强针在初种后约10年时最具成本效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Advisory Committee on Immunization Practices recommends a single dose of the live attenuated herpes zoster vaccine in people aged ≥60 years. Because vaccine-induced protection decreases to zero after 10 years, many vaccinated people will soon be subject to an increased risk of the disease. The study objective was to determine the cost effectiveness of a herpes zoster vaccine booster and its optimal timing among immunocompetent adults first vaccinated at aged ≥60 years. METHODS: A Markov model was built to follow vaccinated individuals for a lifetime. From the societal perspective, costs and quality-adjusted life years were compared between no booster versus booster options. A booster was given any time between 1 and 20 years after the first dose, and for those who had the first dose at different ages: 60, 70, and 80 years. Because people entered the model already vaccinated, costs and side effects of the first dose were not included. The booster was assumed to have the same efficacy and waning rate as the initial vaccination. Model inputs were based on published literature. A cost effectiveness threshold of $100,000/quality-adjusted life year was used. The analysis was conducted in 2016. RESULTS: Cost effectiveness of a booster varied by age and time since vaccination. The booster cost <$100,000/quality-adjusted life year if given >5 years after the initial dose, but was most cost effective at around 10 years. The finding was robust to wide variations in model inputs. CONCLUSIONS: Under current assumptions, a booster dose of herpes zoster vaccine would be cost effective for all vaccinated people 10 years after initial vaccination.
引用
- Le P, Rothberg MB. Cost Effectiveness of a Shingles Vaccine Booster for Currently Vaccinated Adults in the U.S. Am J Prev Med. 2017. PMID: 29153126. doi:10.1016/j.amepre.2017.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。